Ernexa Therapeutics Inc. (NASDAQ:ERNA) Short Interest Down 28.6% in October

Ernexa Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a significant decrease in short interest in October. As of October 15th, there was short interest totaling 39,600 shares, a decrease of 28.6% from the September 30th total of 55,500 shares. Based on an average daily trading volume, of 94,700 shares, the short-interest ratio is presently 0.4 days. Currently, 1.3% of the shares of the company are sold short. Currently, 1.3% of the shares of the company are sold short. Based on an average daily trading volume, of 94,700 shares, the short-interest ratio is presently 0.4 days.

Ernexa Therapeutics Stock Performance

Ernexa Therapeutics stock traded up $0.01 during trading hours on Tuesday, reaching $1.68. 353,463 shares of the stock were exchanged, compared to its average volume of 1,292,394. Ernexa Therapeutics has a 52-week low of $1.09 and a 52-week high of $18.00. The stock has a market cap of $12.89 million, a P/E ratio of -0.02 and a beta of 5.62. The firm’s 50 day moving average is $1.30 and its 200 day moving average is $2.02.

Ernexa Therapeutics (NASDAQ:ERNA) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.61) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.